Disialoganglioside GD2 is a promising target for immunotherapy with expression primarily
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …

In recent years, substantial therapeutic efficacy of antibody-drug conjugates (ADCs) has
been validated through approvals of 16 ADCs for the treatment of malignant tumors …

A universal approach to the construction of antibody–drug conjugates (ADCs) has been
developed. It relies on periodate oxidation of naturally present glycans of immunoglobulin G …

Background Gastric cancer represents a highly lethal malignancy with an elevated mortality
rate among cancer patients, coupled with a suboptimal postoperative survival prognosis …

Trastuzumab emtansine (Kadcyla®) was the first antibody-drug conjugate (ADC) approved
by the Food and Drug Administration in 2013 against a solid tumor, and the first ADC to treat …

Here we report the generation of nanobody dextran polymer conjugates (dextraknobs) that
are loaded with small molecules, ie, fluorophores or photosensitizers, for potential …

Antibody‐directed drugs for targeted cancer treatment have become a hot topic in new
anticancer drug development; however, antibody‐fused therapeutic peptides were rarely …

Oligomerization of antibody fragments via modification with polyethylene glycol (pegylation)
may alter their function and properties, leading to a multivalent interaction of the resulting …

Новые подходы для персонифицированного лечения пациентов с онкологическими
заболеваниями включают разработку инновационных многофункциональных структур …

Ганглиозиды–гликосфинголипиды сложной структуры, состоящие из липидной части–
церамида, заякоренной в липидном бислое клеток, и углеводной части …